Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
S Brown(Center for Biologics Evaluation and Research), M. Miles Braun(Center for Biologics Evaluation and Research), Evelyne T. Edwards(Center for Biologics Evaluation and Research), Sharon K. Gershon(Center for Biologics Evaluation and Research), Mark H. Greene(Cancer Institute (WIA))
Cited by 661
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
<i>Listeria monocytogenes</i> infection as a complication of treatment with tumor necrosis factor α–neutralizing agents
|Arthritis & Rheumatism|2003|387